Delivery of therapeutic proteins to the mucosa using genetically modified microflora.
Drug delivery through mucosal surfaces offers a panorama of opportunities. The advantages are clear and include safety, ease of administration and higher social acceptance, although the major disadvantages are drug availability and appropriate drug targeting. Most mucosa are well equipped to manage the presence of bacteria and many are actually permanently colonised with a specific microflora. Such microbiota may become attractive tools for the delivery of a specific niche of protein therapeutics. These proteins can be produced from genetically modified microbes that are common to the mucosa, and their delivery to the host tissues has been demonstrated. This concept is being developed for the delivery of proteins to the intestine, but has also been applied in delivery to the vagina, nose and mouth.
Steidler
Lothar
L
University College Cork, Alimentary Pharmabiotic Centre, Transgenic Bacteriology, Cork, Ireland. l.steidler@ucc.ie
D000818:Animals; D000906:Antibodies / Q000235:genetics; D001419:Bacteria / Q000235:genetics*; D016207:Cytokines / Q000235:genetics; D016503:Drug Delivery Systems; D005260:Female; D005818:Genetic Engineering; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D009061:Mouth Mucosa / Q000378:metabolism; D009297:Nasal Mucosa / Q000378:metabolism; D011506:Proteins / Q000008:administration & dosage* / Q000235:genetics; D014621:Vagina / Q000378:metabolism
D000906:Antibodies; D016207:Cytokines; D011506:Proteins